Abstracts tagged "biosimilars"

Abstract Number: 438 • 2015 ACR/ARHP Annual Meeting
Comparison of the Stanford and Indian Health Assessment Questionnaires for Disability Outcomes in a Phase 3, Randomized, Double-Blind, Active Comparator Study of Infliximab and Biosimilar Infliximab BOW15 in Rheumatoid Arthritis
Arvind Chopra¹, Manjit Saluja², Alastair Knight³, Lucy Shneyer⁴, Cheryl Lassen⁵, Michael Wyand⁶ and Jonathan Kay⁷, ¹Rheumatology, Centre for Rheumatic Diseases, Pune 411001, India, ²Centre for Rheumatic Diseases, Pune 411001, India, ³Data Management, Evicom Ltd, Twickenham, United Kingdom, ⁴Shneyer Statistics, Denville, NJ, ⁵Epirus Biopharmaceuticals, Zug, Switzerland, ⁶Epirus Biopharmaceuticals, Boston, MA, ⁷University of Massachussets Medical School, Worcester, MA
Background/Purpose: The Stanford Health Assessment Questionnaire (HAQ) includes several questions that are more relevant to rheumatoid arthritis (RA) patients in Western countries than to those…
Abstract Number: 1221 • 2015 ACR/ARHP Annual Meeting
Characteristics and Outcomes of RA Patients Who Start Biosimilar Infliximab in South Korea
Yoon-Kyoung Sung¹, Soo-Kyung Cho¹, Soyoung Won², Chan-Bum Choi³, So-Young Bang⁴, Seung-Jae Hong⁵, Hyoun-Ah Kim⁶, Eunmi Koh⁷, Hye-Soon Lee⁸, Chang-Hee Suh⁹, Dae-Hyun Yoo¹⁰, Sang-Cheol Bae¹ and BIOPSY investigators, ¹Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Clinical Research Center for Rheumatoid Arthritis (CRCRA), Seoul, South Korea, ²Clinical Research Center for Rheumatoid Arthritis (CRCRA), Seoul, South Korea, ³Hanyang University Hospital for Rheumatic Diseases, Clinical Research Center for Rheumatoid Arthritis (CRCRA), Seoul, South Korea, ⁴Hanyang University Guri Hospital, Guri, South Korea, ⁵Division of Rheumatology, Department of Internal Medicine, Kyung Hee University Hospital, Seoul, South Korea, ⁶Ajou University Hospital, Suwon, South Korea, ⁷Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea, ⁸Department of Rheumatology, Hanyang University Guri Hospital, Guri, South Korea, ⁹Department of Rheumatology, Ajou University Hospital, Suwon, South Korea, ¹⁰Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea
Background/Purpose: Recently biosimilar infliximab was approved in South Korea and it has been commonly used for rheumatoid arthritis (RA) patients who are resistant to conventional…
Abstract Number: 2825 • 2014 ACR/ARHP Annual Meeting
A Randomized, Double-Blind, Phase 3 Equivalence Trial Comparing the Etanercept Biosimilar, HD203, with Etanercept (Enbrel^®), in Combination with Methotrexate (MTX) in Patients with Rheumatoid Arthritis (RA)
Sang-Cheol Bae¹, Jinseok Kim², Jung-Yoon Choe³, Won Park⁴, So-Ra Lee⁵, Yongho Ahn⁶ and Yunjeong Seo⁷, ¹Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea, ²Division of Rheumatology, Internal Medicine, Jeju National University, Jeju, Korea, South Korea, ³Division of Rheumatology, Catholic University of Daegu School of Medicine, Daegu, South Korea, ⁴Medicine/Rheumatology, Inha University Hospital, Incheon, South Korea, ⁵Clinical Development/Regulatory Affairs, Hanwha Chemical, Seoul, South Korea, ⁶R&D Center, Hanwha Chemical, Daejeon, South Korea, ⁷Clinical Development, Hanwha Chemical, Seoul, South Korea
Background/Purpose Etanercept is a recombinant fusion protein that blocks TNF activity. HD203 is a biosimilar of etanercept. In a double-blind, randomized study in healthy volunteers,…
Abstract Number: 1509 • 2014 ACR/ARHP Annual Meeting
A Randomized, Double-Blind, Three-Arm, Parallel Group, Single-Dose Study to Compare the Pharmacokinetics, Safety, and Tolerability of Three Formulations of Infliximab (CT-P13, EU-sourced Infliximab and US-sourced Infliximab) in Healthy Volunteers
Dae-Hyun Yoo¹, Won Park², Seung-Cheol Shim³, Chang-Hee Suh⁴, Jihye Yun⁵ and Tina Pyo⁵, ¹Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea, ²Division of Rheumatology, Department of Internal Medicine, Inha University Hospital, Incheon, South Korea, ³Chungnam National University Hospital, Daejeon, South Korea, ⁴Allergy-Rheumatology, Ajou University Hospital, Suwon, South Korea, ⁵CELLTRION, Inc, Incheon, South Korea
Background/Purpose CT-P13 has been approved as the first biosimilar to innovator infliximab sourced from European Union (EU‑INX) in Sep 2013. Even if it has been…
Abstract Number: 1508 • 2014 ACR/ARHP Annual Meeting
Impact of Anti-Drug Antibody on Efficacy and Safety over Week 24 in Both CT-P10 and Innovator Rituximab Treatment Groups
Dae-Hyun Yoo¹, Won Park², Slawomir Jeka³, Fidencio Cons Molina⁴, Pawel Hrycaj⁵, Piotr Wiland⁶, Wolfgang Spieler⁷, Eun Young Lee⁸, Francisco G. Medina-Rodriguez⁹, Pavel Shesternya¹⁰, Sebastiao Radominski¹¹, Dong Hyuk Sheen¹², Mie Jin Lim¹³, Jung-Yoon Choe¹⁴, Leysan Myasoutova¹⁵, Taek Kwon¹⁶, Sang Joon Lee¹⁶, Seung-Cheol Shim¹⁷ and Chang-Hee Suh¹⁸, ¹Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea, ²Division of Rheumatology, Department of Internal Medicine, Inha University Hospital, Incheon, South Korea, ³University Hospital Nr 2 Dr. Jan Biziel, Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in Torun, Clinic of Rheumatology and Connective Tissue Diseases, Bydgoszcz, Poland, ⁴Centro de Investigacion en Artritis y Osteoporosis, Mexicali, Mexico, ⁵Department of Rheumatology and Clinical Immunology, Poznan University of Medical Sciences, Poznan, Poland, ⁶Department of Rheumatology, Medical University of Wroclaw, Wroclaw, Poland, ⁷Osteologie und Rheumatologie, ZeFOR GmbH Zentrum für Forschung, Zerbst, Germany, ⁸Internal Medicine, Seoul National University College of Medicine, Seoul, South Korea, ⁹Centro de Investigación Farmacológica y Biotecnológica, Mexico City, Mexico, ¹⁰Rheumatology Department, Krasnoyarsk State Medical University, Krasnoyarsk, Russia, ¹¹CETI-Centro de estudos em Terapias Inovadoras, Universidade Federal do Parana, Curitiba, Brazil, ¹²Rheumatology, Eulji University Hospital, DaeJeon, South Korea, ¹³Division of Rheumatology, Department of Internal Medicine,, Inha University Hospital, Incheon, South Korea, ¹⁴Division of Rheumatology, Catholic University of Daegu School of Medicine, Daegu, South Korea, ¹⁵City Reumatology Center, Research Medical Complex Vashe Zdorovie, Kazan, Russia, ¹⁶CELLTRION, Inc., Incheon, South Korea, ¹⁷Department of Internal Medicine, Chungnam National University Hospital, Daejeon, South Korea, ¹⁸Allergy-Rheumatology, Ajou University Hospital, Suwon, South Korea
Background/Purpose CT-P10 is a biosimilar candidate for rituximab. Pharmacokinetic equivalence and similarity of clinical efficacy, safety and immunogenicity had been demonstrated between CT-P10 and Innovator…
Abstract Number: 1505 • 2014 ACR/ARHP Annual Meeting
The Biosimilar Landscape: A Systematic Review of Its Current Status
Niti Goel^1,2 and Kamali Chance³, ¹Rheumatology Center of Excellence, Quintiles, Durham, NC, ²Duke University Medical Center, Durham, NC, ³Global Biosimilars Unit, Quintiles, Durham, NC
Background/Purpose In the last 5 years, the number of biosimilars in development for the treatment of immunologic diseases has increased as innovator etanercept (ETA), infliximab (IFX), adalimumab…
Abstract Number: 1502 • 2014 ACR/ARHP Annual Meeting
A Phase I Trial Comparing PF-05280586 (A Potential Biosimilar) and Rituximab in Subjects with Active Rheumatoid Arthritis
Jean-Claude P. Becker¹, Donghua Yin², Lisa Ann Melia³, Ruifeng Li⁴, Barry Gumbiner⁵, Dolca Thomas⁶, George Spencer-Green⁷ and Xu Meng², ¹Pfizer Biosimilars Research and Development/Medical Affairs., Pfizer Inc., New York, NY, ²Clinical Pharmacology/Pharmacometrics, Pfizer Inc., San Diego, CA, ³Biotechnology Clinical Development, Pfizer Inc., San Diego, CA, ⁴Biostatistics, Pfizer Inc., Cambridge, MA, ⁵Worldwide Research and Development, Pfizer Inc., San Diego, CA, ⁶Biosimilars Research and Development Unit, Pfizer Inc., New York, NY, ⁷Worldwide Research and Development, Pfizer Inc., Cambridge, MA
Background/Purpose: PF-05280586, a proposed biosimilar to rituximab, has the same primary amino acid sequence as rituximab with similar physicochemical and in vitro functional properties. This…
Abstract Number: 1501 • 2014 ACR/ARHP Annual Meeting
Immunogenicity Assessment of PF-06438179, a Potential Biosimilar to Infliximab, in Healthy Volunteers
Chandrasekhar Udata¹, Donghua Yin², Chun-hua Cai³, Stephanie Salts⁴, Steven Y. Hua⁴, Muhammad I. Rehman⁵ and Xu Meng², ¹Clinical Pharmacology, Pfizer Inc., San Diego, CA, ²Clinical Pharmacology/Pharmacometrics, Pfizer Inc., San Diego, CA, ³Pfizer Inc., Groton, CT, ⁴Pfizer Inc., San Diego, CA, ⁵Pfizer Inc., Cambridge, MA
Background/Purpose: PF-06438179, a proposed biosimilar to infliximab, was evaluated for immunogenicity in a phase 1 pharmacokinetic (PK) similarity study. Methods: In this double-blind trial (NCT01844804),…
Abstract Number: 1166 • 2014 ACR/ARHP Annual Meeting
5 Year Budget Impact Analysis of Biosimilar Infliximab for the Treatment of Rheumatoid Arthritis in UK, Italy, France and Germany
JiSeon Kim¹, JungAn Hong¹ and Alex Kudrin², ¹CELLTRION HEALTHCARE, INCHEON, South Korea, ²CELLTRION, Inc., Incheon, South Korea
Background/Purpose: Biosimilar infliximab has been approved by EMA based on comparable quality, safety and efficacy profile to infliximab for the management of inflammatory autoimmune disorders…
Abstract Number: L20 • 2014 ACR/ARHP Annual Meeting
BOW015, a Biosimilar Infliximab, in Patients with Active Rheumatoid Arthritis on Stable Methotrexate Doses: 54-Week Results of a Randomized, Double-Blind, Active Comparator Study
Jonathan Kay¹, Michael Wyand², Srikantiah Chandrashekara³, Davy Jacob Olakkengil⁴, Kaushik Bhojani⁵, Girish Bhatia⁶, Gaurav Rathi⁷, Suresh Maroli⁸, Elizabeth Thomson⁹, Cheryl Lassen¹⁰, Lucy Shneyer¹¹ and Arvind Chopra¹², ¹UMass Memorial Medical Center, Worcester, MA, ²Epirus Biopharmaceuticals, Boston, MA, ³Chanre Rheumatology and Immunology Centre and Research, Bangalore, India, ⁴St. John’s Medical College Hospital, Bengaluru, India, ⁵Department of Rheumatology, Fortis Hospital, Mumbai, India, ⁶Pentagon Multispeciality Clinic and Research Centre, Pune, India, ⁷Rathi Hospital, Ahmedabad, India, ⁸Reliance Life Sciences, Mumbai, India, ⁹Elizabeth Thomson LTD, London, MA, United Kingdom, ¹⁰Epirus Biopharmaceuticals, Zug, Switzerland, ¹¹Shneyer Statistics LLC, Denville, NJ, ¹²Rheumatology, Center for Rheumatic Diseases, Pune, India
Background/Purpose: Over the first 16 wks of this phase 3 double-blind (DB) comparative effectiveness clinical trial, the comparable proportion of ACR20 responders for BOW015 (a…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].